Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06938074

Imaging and Treatment Planning for Cardiac Radioablation

Cardiac radioablation is a new treatment for ventricular tachycardia (VT), which uses beams of radiation to treat heart scar that causes VT. To identify the scar areas, magnetic resonance imaging (MRI) and computed tomography (CT) imaging are often used. These are both types of medical imaging that allow clinicians to examine scar area without having to do invasive surgery.

Researchers have developed new heart imaging protocols using both MRI and CT. Their MRI protocol method can now spot both dense and scattered scar tissue. The CT protocol combines multiple different types of scans into a single appointment and uses a special scanner that captures the motion of the heart. For this study, patients will undergo CT and MRI imaging according to these new imaging protocols.

With this study, researchers aim to show that these new imaging protocols can be undergone by patients with ventricular tachycardia and can be used to identify scar. Researchers will also use these scans to make radiation treatment plans to identify which types of treatment can be delivered safely to patients.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Ventricular Tachycardia, Monomorphic Arrhythmias, Cardiac Cardiac Conduction System Disease Cardiovascular Diseases Heart Diseases Ischemia, Myocardial Myocardial Ischemia Pathologic Processes Pathological Conditions, Signs and Symptoms Tachycardia Tachycardia, Ventricular Vascular Diseases Ventricular Tachycardia (V-Tach)

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

London Health Sciences Centre Research Inc

London, Ontario, Canada

Location contact

Stewart Gaede, PhD

CONTACT

[email protected]

5196858600 ext. 53144

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ischemic cardiomyopathy with monomorphic VT
  • Referred by cardiologists
  • 18 years of age or older Exclusion Criteria
  • • Polymorphic ventricular tachycardia
  • Ventricular fibrillation
  • Pregnant or breastfeeding or planning to become pregnant or breastfeed during the study
  • Estimated glomerular filtration rate ≤ 30 mL/min/1.73m2
  • Previous allergic reaction to CT contrast agent Note that participants with contraindications for MRI can still be enrolled in this study but will not undergo MRI parts of this protocol.

Treatment and study plan

CT and MRI

Diagnostic Test

All participants will undergo both CT imaging and MRI imaging to identify areas of ischemic scar. Treatment plans will be created based on CT scans, for all participants using various treatment delivery and motion management techniques.

Primary outcomes

  1. Agreement among cardiologists for target regions, assessed by an inter- and intra-observer variability study using similarity metrics such as the Dice coefficient and Hausdorff distance.

    Time frame: 6 months after conclusion of study

    Imaging protocols will be delivered to participants. Targets will be delineated by experts. Agreement between experts will be assessed..

  2. Adherence of treatment plans to dose constraints and deliverability of treatment plans.

    Time frame: 6 months after conclusion of study

    Treatment plans will be created using various motion management and radiation treatment delivery strategies. Adherence of treatment plans to dose constraints will be assessed by comparing treatment plans to institutional dose constraints. Beam deliverability will be assessed by delivering the treatment plan to a static phantom and comparing the deposited dose to the expected dose. Treatment deliverability, as it relates to motion management, will be assessed by delivering the treatment plan to a moving phantom and comparing the deposited dose to the expected dose.

Secondary outcomes

  1. Agreement between CT/MRI areas of interest (scar), assessed using similarity metrics such as the Dice coefficient and Hausdorff distance.

    Time frame: 6 months after conclusion of study

Study contacts

Contact information is provided by the study sponsor or research team.

Stewart Gaede, PhD

CONTACT

[email protected]

519-685-8600 ext. 53144

Sponsors and collaborators

Lead sponsor

Stewart Gaede

Other

Registry information

Acronym: ITPCR

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Apr 22, 2025
Registry last updated
Sep 26, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.